Your browser doesn't support javascript.
loading
Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial.
Obermair, Andreas; Asher, Rebecca; Pareja, Rene; Frumovitz, Michael; Lopez, Aldo; Moretti-Marques, Renato; Rendon, Gabriel; Ribeiro, Reitan; Tsunoda, Audrey; Behan, Vanessa; Buda, Alessandro; Bernadini, Marcus Q; Zhao, Hongqin; Vieira, Marcelo; Walker, Joan; Spirtos, Nick M; Yao, Shuzhong; Chetty, Naven; Zhu, Tao; Isla, David; Tamura, Mariano; Nicklin, James; Robledo, Kristy P; Gebski, Val; Coleman, Robert L; Salvo, Gloria; Ramirez, Pedro T.
Afiliação
  • Obermair A; Queensland Centre for Gynaecological Cancer Research, University of Queensland, Centre for Clinical Research, RBWH, Herston, QLD Australia. Electronic address: Obermair@powerup.com.au.
  • Asher R; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, Sydney, NSW Australia.
  • Pareja R; Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Bogotá and Clínica de Oncología Astorga, Medellín, Colombia.
  • Frumovitz M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lopez A; Department of Gynecologic Surgery, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Moretti-Marques R; Gynecologic Oncology Division, Oncologic Center, Hospital Israelita Albert Einstein, São Paulo-SP, Brazil.
  • Rendon G; Instituto de Cancerologia-Las Americas, Medellín, Colombia.
  • Ribeiro R; Department of Surgery, Erasto Gaertner Hospital, Curitiba, Brazil.
  • Tsunoda A; Department of Surgery, Erasto Gaertner Hospital, Curitiba, Brazil.
  • Behan V; Queensland Centre for Gynaecological Cancer Research, University of Queensland, Centre for Clinical Research, RBWH, Herston, QLD Australia.
  • Buda A; Unit of Gynecologic Oncology Surgery, Department of Obstetrics and Gynecology, San Gerardo Hospital, Monza MB, Italy.
  • Bernadini MQ; Department of Gynecologic Oncology, Princess Margaret Cancer Center, Ontario, Canada.
  • Zhao H; Department of Gynecology, First Affiliated Hospital of Wenzhou Medical College, Ouhai, Wenzhou, China.
  • Vieira M; Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Brazil.
  • Walker J; Department of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, Norman, OK.
  • Spirtos NM; Division of Gynecologic Oncology, Women's Cancer Center of Nevada, LV.
  • Yao S; Department of Obstetrics and Gynecology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Chetty N; Department of Gynecologic Oncology, Mater Health Services Brisbane, South Brisbane, QLD, Australia.
  • Zhu T; Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Isla D; Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Mexico.
  • Tamura M; Gynecologic Oncology Division, Oncologic Center, Hospital Israelita Albert Einstein, São Paulo-SP, Brazil.
  • Nicklin J; Department of Gynaecologic Oncology, Royal Brisbane and Women's Hospital and The University of Queensland, Brisbane, QLD, Australia.
  • Robledo KP; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, Sydney, NSW Australia.
  • Gebski V; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, Sydney, NSW Australia.
  • Coleman RL; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Salvo G; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ramirez PT; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Am J Obstet Gynecol ; 222(3): 249.e1-249.e10, 2020 03.
Article em En | MEDLINE | ID: mdl-31586602
ABSTRACT

BACKGROUND:

Standard treatment of early cervical cancer involves a radical hysterectomy and retroperitoneal lymph node dissection. The existing evidence on the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer is either nonrandomized or retrospective.

OBJECTIVE:

The purpose of this study was to compare the incidence of adverse events after minimally invasive vs open radical hysterectomy for early cervical cancer. STUDY

DESIGN:

The Laparoscopic Approach to Carcinoma of the Cervix trial was a multinational, randomized noninferiority trial that was conducted between 2008 and 2017, in which surgeons from 33 tertiary gynecologic cancer centers in 24 countries randomly assigned 631 women with International Federation of Gynecology and Obstetrics 2009 stage IA1 with lymph-vascular invasion to IB1 cervical cancer to undergo minimally invasive (n = 319) or open radical hysterectomy (n = 312). The Laparoscopic Approach to Carcinoma of the Cervix trial was suspended for enrolment in September 2017 because of an increased risk of recurrence and death in the minimally invasive surgery group. Here we report on a secondary outcome

measure:

the incidence of intra- and postoperative adverse events within 6 months after surgery.

RESULTS:

Of 631 randomly assigned patients, 536 (85%; mean age, 46.0 years) met inclusion criteria for this analysis; 279 (52%) underwent minimally invasive radical hysterectomy, and 257 (48%) underwent open radical hysterectomy. Of those, 300 (56%), 91 (16.9%), and 69 (12.8%) experienced at least 1 grade ≥2 or ≥3 or a serious adverse event, respectively. The incidence of intraoperative grade ≥2 adverse events was 12% (34/279 patients) in the minimally invasive group vs 10% (26/257) in the open group (difference, 2.1%; 95% confidence interval, -3.3 to 7.4%; P=.45). The overall incidence of postoperative grade ≥2 adverse events was 54% (152/279 patients) in the minimally invasive group vs 48% (124/257) in the open group (difference, 6.2%; 95% confidence interval, -2.2 to 14.7%; P=.14).

CONCLUSION:

For early cervical cancer, the use of minimally invasive compared with open radical hysterectomy resulted in a similar overall incidence of intraoperative or postoperative adverse events.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Complicações Pós-Operatórias / Neoplasias do Colo do Útero / Histerectomia / Complicações Intraoperatórias Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Am J Obstet Gynecol Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Complicações Pós-Operatórias / Neoplasias do Colo do Útero / Histerectomia / Complicações Intraoperatórias Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Am J Obstet Gynecol Ano de publicação: 2020 Tipo de documento: Article